ReviewCurrent neuropharmacology2017
Current and Future Issues in the Development of Spinal Agents for the Management of Pain.
Review in Current neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Comparative Efficacy and Safety of 11 Drugs as Therapies for Adults With Neuropathic Pain After Spinal Cord Injury: A Bayesian Network Analysis Based on 20 Randomized Controlled Trials.Frontiers in neurology · 2022Pooled it
- Optimizing ketamine dosing strategies across diverse clinical applications: a comprehensive review.Annals of medicine and surgery (2012) · 2025Review
- Relationship between neuroinflammatory markers in plasma and cerebrospinal fluid before and after hip arthroplasty and postoperative delirium.American journal of translational research · 2025Article
- A perspective: neuraxial therapeutics in pain management: now and future.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- In vivo distribution of cerebrospinal fluid tracer in human upper spinal cord and brain stem.JCI insight · 2023Article
- The glymphatic system: implications for drugs for central nervous system diseases.Nature reviews. Drug discovery · 2022Review
- The Options for Neuraxial Drug Administration.CNS drugs · 2022Review
- Novel Therapies for the Treatment of Neuropathic Pain: Potential and Pitfalls.Journal of clinical medicine · 2022Review
- The differentialFrontiers in pharmacology · 2022Article
- Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Glial-Neuronal Interactions in Pathogenesis and Treatment of Spinal Cord Injury.International journal of molecular sciences · 2021Review
- Effects of fadolmidine, an αPharmacology research & perspectives · 2021Article
- Grand Challenges in Neuromodulatory Interventions.Frontiers in pain research (Lausanne, Switzerland) · 2021Article
- Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials.Frontiers in pharmacology · 2021Review
- Ionized or Total Magnesium levels, what should we measure in critical ill patients?Translational medicine @ UniSa · 2020Article
- Pharmacodynamics of intrathecal and epidural fadolmidine, an αNaunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Frontiers in Pain Research: A Scope of Its Focus and Content.Frontiers in pain research (Lausanne, Switzerland) · 2020Article
- Pain inhibition through transplantation of fetal neuronal progenitors into the injured spinal cord in rats.Neural regeneration research · 2019Article
- Characterization of Effect of Repeated Bolus or Continuous Intrathecal Infusion of Morphine on Spinal Mass Formation in the Dog.Neuromodulation : journal of the International Neuromodulation Society · 2019Article
- Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor Signaling.Anesthesiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Targeting analgesic drugs for spinal delivery reflects the fact that while the conscious experience of pain is mediated supraspinally, input initiated by high intensity stimuli, tissue injury and/or nerve injury is encoded at the level of the spinal dorsal horn and this output informs the brain as to the peripheral environment. This encoding process is subject to strong upregulation resulting in hyperesthetic states and downregulation reducing the ongoing processing of nociceptive stimuli reversing the hyperesthesia and pain processing. The present review addresses the biology of spinal nociceptive processing as relevant to the effects of intrathecally-delivered drugs in altering pain processing following acute stimulation, tissue inflammation/injury and nerve injury. The review covers i) the major classes of spinal agents currently employed as intrathecal analgesics (opioid agonists, alpha 2 agonists; sodium channel blockers; calcium channel blockers; NMDA blockers; GABA A/B agonists; COX inhibitors; ii) ongoing developments in the pharmacology of spinal therapeutics focusing on less studied agents/targets (cholinesterase inhibition; Adenosine agonists; iii) novel intrathecal targeting methodologies including gene-based approaches (viral vectors, plasmids, interfering RNAs); antisense, and toxins (botulinum toxins; resniferatoxin, substance P Saporin); and iv) issues relevant to intrathecal drug delivery (neuraxial drug distribution), infusate delivery profile, drug dosing, formulation and principals involved in the preclinical evaluation of intrathecal drug safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.